Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.

Amlodipine Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Atorvastatin Blood Pressure Calcium Calcium Channel Blockers Diabetes Mellitus, Type 2 Follow-Up Studies Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemia Hypertension Perindopril

ACE inhibitors Amlodipine Atorvastatin Hyper-cholesterolemia Hypertension Perindopril Statins

Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD

ISSN: 1590-3729

Titre abrégé: Nutr Metab Cardiovasc Dis

Pays: Netherlands

ID NLM: 9111474

Informations de publication

Date de publication:
09 2022

Historique:

received: 09 05 2022

revised: 12 06 2022

accepted: 17 06 2022

pubmed: 18 7 2022

medline: 31 8 2022

entrez: 17 7 2022

Statut: ppublish

Résumé

To evaluate the long-term effect of simultaneous treatment of hypertension and hypercholesterolemia with angiotensin-converting enzyme (ACE) inhibitors and statins on the incidence of major cardiovascular events (MACE) and other clinical outcomes. We considered data from a subset of Brisighella Heart Study (BHS) participants who were consecutively evaluated in three epidemiological surveys between 2012 and 2020. We excluded normotensive subjects and individuals with a low calculated 10-year CVD risk, hypertensive patients treated with antihypertensive drugs different from ACE inhibitors and patients who changed antihypertensive medications during follow-up. The remaining participants were divided into four groups depending on whether they were treated with (I) perindopril ± amlodipine without statin treatment (N. 132), (II) perindopril ± amlodipine and atorvastatin (N. 132), (III) an ACE inhibitor other than perindopril ± a calcium-channel blocker without statin therapy (N. 133), (IV) an ACE inhibitor other than perindopril ± a calcium-channel blocker and statin therapy (N. 145). The long-term (8 years) effects of the different combined treatment were compared among the pre-defined groups. Over the follow-up period of 8 years, the proportion of subjects who developed MACE, type 2 diabetes mellitus and hyperuricemia, and the proportion of subjects needing for the intensification of antihypertensive treatment to improve blood pressure control were statistically different among the predefined groups (P < 0.05). Combined treatment with ACE inhibitors and statins (especially atorvastatin) in hypertensive patients seems to significantly reduce the risk of developing CVD in comparison with treatment with ACE inhibitors alone.

Sections du résumé

BACKGROUND AND AIMS

METHODS AND RESULTS

We considered data from a subset of Brisighella Heart Study (BHS) participants who were consecutively evaluated in three epidemiological surveys between 2012 and 2020. We excluded normotensive subjects and individuals with a low calculated 10-year CVD risk, hypertensive patients treated with antihypertensive drugs different from ACE inhibitors and patients who changed antihypertensive medications during follow-up. The remaining participants were divided into four groups depending on whether they were treated with (I) perindopril ± amlodipine without statin treatment (N. 132), (II) perindopril ± amlodipine and atorvastatin (N. 132), (III) an ACE inhibitor other than perindopril ± a calcium-channel blocker without statin therapy (N. 133), (IV) an ACE inhibitor other than perindopril ± a calcium-channel blocker and statin therapy (N. 145). The long-term (8 years) effects of the different combined treatment were compared among the pre-defined groups. Over the follow-up period of 8 years, the proportion of subjects who developed MACE, type 2 diabetes mellitus and hyperuricemia, and the proportion of subjects needing for the intensification of antihypertensive treatment to improve blood pressure control were statistically different among the predefined groups (P < 0.05).

CONCLUSION

Combined treatment with ACE inhibitors and statins (especially atorvastatin) in hypertensive patients seems to significantly reduce the risk of developing CVD in comparison with treatment with ACE inhibitors alone.

Identifiants

DOI: 10.1016/j.numecd.2022.06.017 PMID: 35843791

pubmed: 35843791

pii: S0939-4753(22)00282-4

doi: 10.1016/j.numecd.2022.06.017

pii:

doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0

Antihypertensive Agents 0

Calcium Channel Blockers 0

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Amlodipine 1J444QC288

Atorvastatin A0JWA85V8F

Calcium SY7Q814VUP

Perindopril Y5GMK36KGY

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

2246-2254

Investigateurs

A F G Cicero (AFG)

S D'Addato (S)

F Fogacci (F)

M Giovannini (M)

E Grandi (E)

E Rizzoli (E)

F Ventura (F)

P Coppola (P)

E Ianniello (E)

M Soldati (M)

F M Piani (FM)

I R Iamino (IR)

S Palmisano (S)

M Landolfo (M)

S Bacchelli (S)

C Borghi (C)

Informations de copyright

Copyright © 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.